Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Potassium Channel Tetramerisation Domain Containing 17 (KCTD17) (Middle Region) Peptid

KCTD17 Reaktivität: Human Wirt: Synthetic BP, WB
Produktnummer ABIN5672785

Kurzübersicht für Potassium Channel Tetramerisation Domain Containing 17 (KCTD17) (Middle Region) Peptid (ABIN5672785)

Target

KCTD17 (Potassium Channel Tetramerisation Domain Containing 17 (KCTD17))

Spezies

Human

Quelle

  • 3
Synthetic

Applikation

Blocking Peptide (BP), Western Blotting (WB)
  • Protein Region

    Middle Region

    Sequenz

    DQAEFLCVVS KELHSTPNGL SSESSRKTKS TEEQLEEQQQ QEEEVEEVEV

    Produktmerkmale

    This is a synthetic peptide designed for use in combination with anti- KCTD17 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target

    KCTD17 (Potassium Channel Tetramerisation Domain Containing 17 (KCTD17))

    Hintergrund

    Is a positive regulator of ciliogenesis, playing a crucial role in the initial steps of axoneme extension. It acts as a substrate-adapter for CUL3-RING ubiquitin ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of TCHP, a protein involved in ciliogenesis down-regulation. May be involved in endoplasmic reticulum calcium ion homeostasis.

    Protein Size: 321

    Gen-ID

    79734

    NCBI Accession

    NM_001282684, NP_001269613

    UniProt

    Q8N5Z5
Sie sind hier:
Chat with us!